Page 202 - 2019_03-Haematologica-web

D.P. Hart et al.
edition). UK Haemophilia Centre Doctors
Organization. Br J Haematol. 2013;160(2):
153–170.
6. Fischer K, Iorio A, Lassila R, et al. Inhibitor
development in non-severe haemophilia across Europe. Thromb Haemost. 2015;114 (4): 670–675.
7. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998;4(4):558–563.
8. Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemo- philia A. Blood. 2013;122(11):1954–1962.
9. Batty P, Austin SK, Khair K, et al. Treatment burden, haemostatic strategies and real world inhibitor screening practice in non- severe haemophilia A. Br J Haematol. 2017;176(5):796–804.
10. Hvas A-M, Poulsen LH. Inhibitor screening in non-severe haemophilia patients; a major challenge. Br J Haematol. 2017;176(5):683– 685.
11. van Velzen AS, Eckhardt CL, Hart DP, et al. Inhibitors in nonsevere haemophilia A: out- come and eradication strategies. Thromb Haemost. 2015;114(1):46–55.
12. van Velzen AS, Eckhardt CL, Streefkerk N, et al. The incidence and treatment of bleed- ing episodes in non-severe haemophilia A patients with inhibitors. Thromb Haemost. 2016;115(3):543–550.
13. James EA, Van Haren SD, Ettinger RA, et al. T-cell responses in two unrelated hemophil- ia A inhibitor subjects include an epitope at the factor VIII R593C missense site: T-cell responses to a FVIII missense site in hemo- philia A. J Thromb Haemost. 2011;9(4):689– 699.
14. Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. HLA-DR-restricted
T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia. 2010;16 (102):44–55.
15. James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immuno- genicity of the corresponding self-peptide. J Thromb Haemost. 2007;5(12): 2399–2407.
16. Whelan SFJ, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody respons- es against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013;121(6):1039–1048.
17. Derbinski J, Kyewski B. How thymic anti- gen presenting cells sample the body’s self- antigens. Curr Opin Immunol. 2010;22(5): 592–600.
tein space at the Universal Protein Resource (UniProt). Nucleic Acids Res. 2012;40(D1): D71-75.
24. Yates A, Akanni W, Amode MR, et al. Ensembl 2016. Nucleic Acids Res. 2016;44(D1):D710-716.
25. Lazarski CA, Chaves FA, Jenks SA, et al. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity. 2005;23(1): 29–40.
26. Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009;360 (16):1618–1627.
27. 1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for human genetic variation. Nature. 2015;526 (7571):68–74.
28. Hsing LC, Rudensky AY. The lysosomal cys- teine proteases in MHC class II antigen pres- entation. Immunol Rev. 2005;207(1):229–
18. Shepherd AJ, Skelton S, Sansom CE, Gomez
K, Moss DS, Hart DP. A large-scale compu-
tational study of inhibitor risk in non-severe haemophilia A. Br J Haematol. 2015;168(3): 241.
413–420.
19. Davidson CJ, Hirt RP, Lal K, et al. Molecular
evolution of the vertebrate blood coagula- tion network. Thromb Haemost. 2003;89(3): 420–428.
20. Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 2009;10(1):296.
21. Southwood S, Sidney J, Kondo A, et al. Several common HLA-DR types share large- ly overlapping peptide binding repertoires. J Immunol. 1998;160(7):3363–3373.
22. Wang P, Sidney J, Kim Y, et al. Peptide bind- ing predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics. 2010;11 (1):568.
23. UniProt Consortium. Reorganizing the pro-
29. Kersh GJ, Miley MJ, Nelson CA, et al. Structural and functional consequences of altering a peptide MHC anchor residue. J Immunol. 2001;166(5):3345–3354.
30. Deng L, Langley RJ, Brown PH, et al. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nat Immunol. 2007;8(4):398–408.
31. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and corecep- tors. Annu Rev Immunol. 2006;24:419–466.
32. Jennings IA, Kitchen D, Kitchen S, et al. Variation in practice for FVIII and FIX inhibitor investigations - results from a UK NEQAS (Blood Coagulation) and UK HCDO multicentre exercise. Res Pract Thromb Haemost. 2017;1(S1):525.
608
haematologica | 2019; 104(3)